305 related articles for article (PubMed ID: 36632321)
1. Nuclear factor erythroid 2-related factor 2-mediated signaling and metabolic associated fatty liver disease.
Bukke VN; Moola A; Serviddio G; Vendemiale G; Bellanti F
World J Gastroenterol; 2022 Dec; 28(48):6909-6921. PubMed ID: 36632321
[TBL] [Abstract][Full Text] [Related]
2. A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease.
Hammoutene A; Laouirem S; Albuquerque M; Colnot N; Brzustowski A; Valla D; Provost N; Delerive P; Paradis V;
JHEP Rep; 2023 Oct; 5(10):100845. PubMed ID: 37663119
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.
Mohs A; Otto T; Schneider KM; Peltzer M; Boekschoten M; Holland CH; Hudert CA; Kalveram L; Wiegand S; Saez-Rodriguez J; Longerich T; Hengstler JG; Trautwein C
J Hepatol; 2021 Mar; 74(3):638-648. PubMed ID: 33342543
[TBL] [Abstract][Full Text] [Related]
4. Network pharmacology-based identification of significant pathway for protection of Yinhuang granule in a mice model of metabolic-associated fatty liver disease.
Yan S; Zhang S; Du A; Miao H; Lu B; Huang Z; Ji L
Phytomedicine; 2021 Oct; 91():153666. PubMed ID: 34339944
[TBL] [Abstract][Full Text] [Related]
5. Silybin Alleviates Hepatic Steatosis and Fibrosis in NASH Mice by Inhibiting Oxidative Stress and Involvement with the Nf-κB Pathway.
Ou Q; Weng Y; Wang S; Zhao Y; Zhang F; Zhou J; Wu X
Dig Dis Sci; 2018 Dec; 63(12):3398-3408. PubMed ID: 30191499
[TBL] [Abstract][Full Text] [Related]
6. The Dual Role of Nrf2 in Nonalcoholic Fatty Liver Disease: Regulation of Antioxidant Defenses and Hepatic Lipid Metabolism.
Chambel SS; Santos-Gonçalves A; Duarte TL
Biomed Res Int; 2015; 2015():597134. PubMed ID: 26120584
[TBL] [Abstract][Full Text] [Related]
7. Neutrophil: An emerging player in the occurrence and progression of metabolic associated fatty liver disease.
Chen S; Guo H; Xie M; Zhou C; Zheng M
Int Immunopharmacol; 2021 Aug; 97():107609. PubMed ID: 33887577
[TBL] [Abstract][Full Text] [Related]
8. Hesperetin ameliorates hepatic oxidative stress and inflammation
Li J; Wang T; Liu P; Yang F; Wang X; Zheng W; Sun W
Food Funct; 2021 May; 12(9):3898-3918. PubMed ID: 33977953
[TBL] [Abstract][Full Text] [Related]
9. PSA controls hepatic lipid metabolism by regulating the NRF2 signaling pathway.
Huang B; Xiong X; Zhang L; Liu X; Wang Y; Gong X; Sang Q; Lu Y; Qu H; Zheng H; Zheng Y
J Mol Cell Biol; 2021 Oct; 13(7):527-539. PubMed ID: 34048566
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 in alcoholic liver disease.
Sun J; Fu J; Li L; Chen C; Wang H; Hou Y; Xu Y; Pi J
Toxicol Appl Pharmacol; 2018 Oct; 357():62-69. PubMed ID: 30165058
[TBL] [Abstract][Full Text] [Related]
11. Experimental nonalcoholic fatty liver disease in mice leads to cytochrome p450 2a5 upregulation through nuclear factor erythroid 2-like 2 translocation.
Cui Y; Wang Q; Li X; Zhang X
Redox Biol; 2013; 1(1):433-40. PubMed ID: 24191237
[TBL] [Abstract][Full Text] [Related]
12. Free radicals, antioxidants, nuclear factor-E2-related factor-2 and liver damage.
Ramos-Tovar E; Muriel P
Vitam Horm; 2023; 121():271-292. PubMed ID: 36707137
[TBL] [Abstract][Full Text] [Related]
13. Macrophages in metabolic associated fatty liver disease.
Alharthi J; Latchoumanin O; George J; Eslam M
World J Gastroenterol; 2020 Apr; 26(16):1861-1878. PubMed ID: 32390698
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of NRF2 is correlated with the magnitude of inflammation and fibrosis in chronic liver disease.
To K; Okada K; Watahiki T; Suzuki H; Tsuchiya K; Tokushige K; Yamamoto M; Ariizumi SI; Shoda J
Cancer Med; 2023 Oct; 12(19):19423-19437. PubMed ID: 37732511
[TBL] [Abstract][Full Text] [Related]
15. Gentiopicroside Ameliorates Oxidative Stress and Lipid Accumulation through Nuclear Factor Erythroid 2-Related Factor 2 Activation.
Jin M; Feng H; Wang Y; Yan S; Shen B; Li Z; Qin H; Wang Q; Li J; Liu G
Oxid Med Cell Longev; 2020; 2020():2940746. PubMed ID: 32655764
[TBL] [Abstract][Full Text] [Related]
16. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
Shimozono R; Asaoka Y; Yoshizawa Y; Aoki T; Noda H; Yamada M; Kaino M; Mochizuki H
Mol Pharmacol; 2013 Jul; 84(1):62-70. PubMed ID: 23592516
[TBL] [Abstract][Full Text] [Related]
17. Nuclear erythroid 2-related factor 2: a novel potential therapeutic target for liver fibrosis.
Yang JJ; Tao H; Huang C; Li J
Food Chem Toxicol; 2013 Sep; 59():421-7. PubMed ID: 23793039
[TBL] [Abstract][Full Text] [Related]
18. Carbon monoxide releasing molecule-A1 improves nonalcoholic steatohepatitis via Nrf2 activation mediated improvement in oxidative stress and mitochondrial function.
Upadhyay KK; Jadeja RN; Vyas HS; Pandya B; Joshi A; Vohra A; Thounaojam MC; Martin PM; Bartoli M; Devkar RV
Redox Biol; 2020 Jan; 28():101314. PubMed ID: 31514051
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease.
Khanmohammadi S; Kuchay MS
Pharmacol Res; 2022 Nov; 185():106507. PubMed ID: 36252773
[TBL] [Abstract][Full Text] [Related]
20. Nonalcoholic steatohepatitis and mechanisms by which it is ameliorated by activation of the CNC-bZIP transcription factor Nrf2.
Bathish B; Robertson H; Dillon JF; Dinkova-Kostova AT; Hayes JD
Free Radic Biol Med; 2022 Aug; 188():221-261. PubMed ID: 35728768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
